July 2022
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
"HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies
Tokyo, Japan, London and Cambridge, UK, 22 July 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial."
Comments